ADRENALIN (epinephrine) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2012.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
ADRENALIN (epinephrine) is a potent alpha-adrenergic agonist administered via intramuscular, intravenous, or subcutaneous injection in solution form. It is the first-line emergency treatment for anaphylaxis and acute hypotension, working by stimulating adrenergic receptors to increase heart rate, blood pressure, and airway patency. The product is indicated for rapid reversal of life-threatening allergic and cardiovascular collapse.
Peak lifecycle stage with established market presence and stable Medicare demand indicates mature team structure focused on market maintenance rather than rapid expansion.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Worked on ADRENALIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ADRENALIN offers career stability in a high-impact, life-critical product with market leadership and zero competitive threats, making it ideal for professionals seeking to master mature brand management and market defense strategies. However, limited clinical development and growth trajectory mean career advancement will require lateral moves or transition planning before 2030 as LOE approaches.